Schizophrenia
Welcome,         Profile    Billing    Logout  
 86 Companies   137 Products   137 Products   85 Mechanisms of Action   4 Trials   2019 News 


12345678910111213...3940»
  • ||||||||||  Enrollment change:  Antipsychotic Medication Extended Dosing Study (clinicaltrials.gov) -  Feb 15, 2024   
    P=N/A,  N=120, Completed, 
    Trial completion date: Jul 2025 --> Jul 2026 | Trial primary completion date: Jul 2024 --> Jul 2025 N=40 --> 120
  • ||||||||||  iloperidone / Generic mfg.
    Enrollment change:  REPRIEVE: Relapse Prevention Study in Patients With Schizophrenia (clinicaltrials.gov) -  Jul 17, 2023   
    P3,  N=635, Completed, 
    Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2023 --> Jul 2024 N=303 --> 635
  • ||||||||||  Enrollment closed, Trial completion date, Trial primary completion date:  Tai Chi Effects on Chronic Insomnia in Breast Cancer Survivors: Immune Mechanisms (clinicaltrials.gov) -  Mar 14, 2023   
    P=N/A,  N=90, Active, not recruiting, 
    N=60 --> 86 Completed --> Active, not recruiting | Trial completion date: Jul 2012 --> Jul 2024 | Trial primary completion date: Jul 2012 --> Jul 2023
  • ||||||||||  olanzapine / Generic mfg., clozapine / Generic mfg.
    Enrollment change, Adverse events:  Alleviating the Metabolic Side Effects of Antipsychotic Medications (clinicaltrials.gov) -  Apr 24, 2019   
    P4,  N=0, Withdrawn, 
    Completed --> Active, not recruiting | Trial completion date: Jul 2012 --> Jul 2024 | Trial primary completion date: Jul 2012 --> Jul 2023 N=90 --> 0
  • ||||||||||  paliperidone extended release / Generic mfg.
    Trial completion, Enrollment change:  Paliperidone ER(Invega (clinicaltrials.gov) -  Apr 20, 2019   
    P4,  N=11, Completed, 
    N=90 --> 0 Recruiting --> Completed | N=70 --> 11
  • ||||||||||  aripiprazole / Generic mfg.
    Enrollment change:  Validation of Receptor Occupancy Simulation (clinicaltrials.gov) -  Apr 20, 2019   
    P=N/A,  N=7, Completed, 
    Active, not recruiting --> Completed | Trial completion date: Apr 2020 --> Apr 2019 N=20 --> 7
  • ||||||||||  Trial completion:  Fingolimod in Schizophrenia Patients (clinicaltrials.gov) -  Apr 20, 2019   
    P2,  N=40, Completed, 
    N=20 --> 7 Active, not recruiting --> Completed
  • ||||||||||  Trial completion:  Understanding How Cognitive Remediation Works (clinicaltrials.gov) -  Mar 13, 2019   
    P=N/A,  N=203, Completed, 
    Recruiting --> Completed Active, not recruiting --> Completed
  • ||||||||||  Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  Cross-Sectional Iloperidone IVGTT (clinicaltrials.gov) -  Mar 12, 2019   
    P=N/A,  N=37, Completed, 
    Active, not recruiting --> Completed Recruiting --> Completed | N=60 --> 37 | Trial completion date: Dec 2015 --> May 2016 | Trial primary completion date: Dec 2015 --> May 2016
  • ||||||||||  olanzapine / Generic mfg., sertraline / Generic mfg.
    Trial completion, Trial completion date, Trial primary completion date:  STOP-PD: Sustaining Remission of Psychotic Depression (clinicaltrials.gov) -  Mar 5, 2019   
    P4,  N=269, Completed, 
    Recruiting --> Completed | N=60 --> 37 | Trial completion date: Dec 2015 --> May 2016 | Trial primary completion date: Dec 2015 --> May 2016 Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Nov 2017 | Trial primary completion date: Mar 2018 --> Nov 2017
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion:  Cognitive Remediation and Sheltered Employment in Schizophrenia (clinicaltrials.gov) -  Feb 25, 2019   
    P=N/A,  N=79, Completed, 
    Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Nov 2017 | Trial primary completion date: Mar 2018 --> Nov 2017 Active, not recruiting --> Completed
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion, Enrollment change, Adverse events:  Monitoring and Management for Metabolic Side Effects of Antipsychotics (clinicaltrials.gov) -  Feb 12, 2019   
    P=N/A,  N=12, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed | N=103 --> 12
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion:  Glutamate, Brain Connectivity and Duration of Untreated Psychosis (clinicaltrials.gov) -  Jan 22, 2019   
    P=N/A,  N=134, Completed, 
    Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Jun 2017 Recruiting --> Completed
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion:  Remote Cognitive Remediation (clinicaltrials.gov) -  Nov 15, 2018   
    P=N/A,  N=100, Completed, 
    Trial completion date: Dec 2012 --> Jun 2017 Recruiting --> Completed
  • ||||||||||  olanzapine / Generic mfg., sertraline / Generic mfg.
    Trial completion date, Trial primary completion date:  STOP-PD: Sustaining Remission of Psychotic Depression (clinicaltrials.gov) -  Sep 17, 2018   
    P4,  N=269, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Dec 2016 --> Jun 2016 Trial completion date: Jul 2018 --> Dec 2018 | Trial primary completion date: Jul 2018 --> Mar 2018
  • ||||||||||  metformin / Generic mfg., clozapine / Generic mfg.
    Enrollment change, Trial termination:  The Effect of Metformin on Obesity and Metabolic Disturbance in Patients Taking Clozapine (clinicaltrials.gov) -  Sep 7, 2018   
    P4,  N=15, Terminated, 
    Trial completion date: Jul 2018 --> Dec 2018 | Trial primary completion date: Jul 2018 --> Mar 2018 N=30 --> 15 | Recruiting --> Terminated; Failure to recruit the planned number of participants
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis (clinicaltrials.gov) -  Aug 27, 2018   
    P=N/A,  N=88, Completed, 
    N=30 --> 15 | Recruiting --> Terminated; Failure to recruit the planned number of participants Suspended --> Completed | N=264 --> 88 | Trial completion date: Mar 2019 --> Jul 2018 | Trial primary completion date: Mar 2019 --> Jul 2018
  • ||||||||||  Trial completion:  Reducing the Weight of Overweight Schizophrenia Patients (clinicaltrials.gov) -  Aug 22, 2018   
    P=N/A,  N=261, Completed, 
    Suspended --> Completed | N=264 --> 88 | Trial completion date: Mar 2019 --> Jul 2018 | Trial primary completion date: Mar 2019 --> Jul 2018 Active, not recruiting --> Completed
  • ||||||||||  Phase classification:  Cognitive Training to Enhance VA Work Program Outcomes (clinicaltrials.gov) -  Aug 20, 2018   
    P=N/A,  N=77, Completed, 
    Active, not recruiting --> Completed Phase classification: P3 --> P=N/A
  • ||||||||||  linagliptin / Generic mfg.
    Trial termination:  Linagliptin in Schizophrenia Patients (clinicaltrials.gov) -  Aug 16, 2018   
    P1,  N=1, Terminated, 
    Phase classification: P3 --> P=N/A Suspended --> Terminated; Inability to obtain patients
  • ||||||||||  metformin / Generic mfg.
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  Metformin in Co-morbid Diabetes or Prediabetes and Serious Mental Illness (clinicaltrials.gov) -  Jul 30, 2018   
    P4,  N=35, Completed, 
    N=18 --> 12 | Recruiting --> Terminated; low enrollment due to limited resources Recruiting --> Completed | N=24 --> 35 | Trial completion date: Jun 2018 --> Mar 2018 | Trial primary completion date: Jun 2018 --> Feb 2018
  • ||||||||||  Trial completion, Phase classification:  Study of Vitamin D in the Severely Mentally Ill (clinicaltrials.gov) -  Jul 19, 2018   
    P4,  N=40, Completed, 
    Recruiting --> Completed | N=24 --> 35 | Trial completion date: Jun 2018 --> Mar 2018 | Trial primary completion date: Jun 2018 --> Feb 2018 Active, not recruiting --> Completed | Phase classification: PN/A --> P4
  • ||||||||||  tolcapone / Generic mfg.
    Trial termination:  Clinical Trial of Tolcapone for Cognition in Schizophrenia (clinicaltrials.gov) -  Jul 17, 2018   
    P2,  N=210, Terminated, 
    Active, not recruiting --> Completed | Phase classification: PN/A --> P4 Completed --> Terminated; Scientific Director request to use resources for other studies
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion, Enrollment change:  Home Treatment for Acute Psychiatric Care (clinicaltrials.gov) -  Jun 6, 2018   
    P=N/A,  N=707, Completed, 
    N=48 --> 0 | Recruiting --> Withdrawn Recruiting --> Completed | N=500 --> 707
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion:  Exercise and Cognitive Training (clinicaltrials.gov) -  Jun 4, 2018   
    P=N/A,  N=30, Completed, 
    Recruiting --> Completed | N=500 --> 707 Active, not recruiting --> Completed